Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVMNASDAQ:DMACNASDAQ:ELDNNASDAQ:INBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$2.51+3.3%$2.99$1.78▼$10.14$52.44M1.03267,100 shs338,959 shsDMACDiaMedica Therapeutics$4.12-1.2%$3.89$2.14▼$6.82$176.68M1.2982,853 shs166,026 shsELDNEledon Pharmaceuticals$3.17+3.6%$3.06$2.30▼$5.54$189.83M0.08274,352 shs132,409 shsINBXInhibrx$13.53+4.4%$12.36$10.80▼$18.95$195.86MN/A116,019 shs78,775 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+3.29%+10.57%-28.08%-42.95%-67.61%DMACDiaMedica Therapeutics-1.20%-0.72%-2.60%-32.24%+39.66%ELDNEledon Pharmaceuticals+3.59%+0.63%-4.23%-19.54%+13.21%INBXInhibrx+4.40%+3.05%+11.36%-1.17%-24.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0442 of 5 stars3.41.00.04.82.72.50.6DMACDiaMedica Therapeutics1.583 of 5 stars3.52.00.00.02.60.00.0ELDNEledon Pharmaceuticals2.7245 of 5 stars3.54.00.00.03.11.70.0INBXInhibrx2.3419 of 5 stars0.01.00.04.63.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$26.40951.79% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.0094.17% UpsideELDNEledon Pharmaceuticals 3.00Buy$12.50294.32% UpsideINBXInhibrx 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ADVM, DMAC, ELDN, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/15/2025ADVMAdverum BiotechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.005/15/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.005/15/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025INBXInhibrxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/17/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $33.004/16/2025ADVMAdverum BiotechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.004/16/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/19/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M52.44N/AN/A$8.26 per share0.30DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AINBXInhibrx$200K979.30N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$6.40N/AN/AN/AN/A-65.14%-40.52%8/11/2025 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.64N/AN/AN/AN/A-43.67%-40.81%8/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$116.54M-$2.10N/AN/AN/AN/A-189.99%-28.17%8/18/2025 (Estimated)INBXInhibrx-$154.96M$116.750.12N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)Latest ADVM, DMAC, ELDN, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/14/2025Q4 2024INBXInhibrx-$2.55-$2.80-$0.25-$2.80N/AN/A5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A4/15/2025Q4 2024ADVMAdverum Biotechnologies-$1.34-$1.96-$0.62-$1.96N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/17/2025Q4 2024DMACDiaMedica Therapeutics-$0.17-$0.18-$0.01-$0.18N/AN/A3/17/2025Q4 2024INBXInhibrx-$2.88-$3.09-$0.21-$3.09N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AINBXInhibrxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A5.825.82DMACDiaMedica TherapeuticsN/A11.8111.81ELDNEledon PharmaceuticalsN/A6.536.53INBXInhibrxN/A4.704.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%DMACDiaMedica Therapeutics10.12%ELDNEledon Pharmaceuticals56.77%INBXInhibrx82.46%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies4.20%DMACDiaMedica Therapeutics7.30%ELDNEledon Pharmaceuticals12.30%INBXInhibrx17.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.93 millionOptionableDMACDiaMedica Therapeutics2042.88 million39.68 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableINBXInhibrx16614.48 million11.26 millionOptionableADVM, DMAC, ELDN, and INBX HeadlinesRecent News About These CompaniesDeutsche Bank AG Takes $302,000 Position in Inhibrx, Inc. (NASDAQ:INBX)June 1 at 3:36 AM | marketbeat.comMillennium Management LLC Buys Shares of 258,388 Inhibrx, Inc. (NASDAQ:INBX)May 31, 2025 | marketbeat.comAlpha Wealth Funds LLC Buys New Stake in Inhibrx, Inc. (NASDAQ:INBX)May 29, 2025 | marketbeat.com116,104 Shares in Inhibrx, Inc. (NASDAQ:INBX) Acquired by Northern Trust CorpMay 28, 2025 | marketbeat.comJane Street Group LLC Buys New Shares in Inhibrx, Inc. (NASDAQ:INBX)May 22, 2025 | marketbeat.comSanofi Takes $17.83 Million Position in Inhibrx, Inc. (NASDAQ:INBX)May 19, 2025 | marketbeat.comLaird Norton Wetherby Wealth Management LLC Invests $472,000 in Inhibrx, Inc. (NASDAQ:INBX)May 18, 2025 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial ResultsMay 16, 2025 | finanznachrichten.deInhibrx Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comCaption Management LLC Takes $3.08 Million Position in Inhibrx, Inc. (NASDAQ:INBX)May 8, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Makes New Investment in Inhibrx, Inc. (NASDAQ:INBX)May 8, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Purchases Shares of 160,899 Inhibrx, Inc. (NASDAQ:INBX)May 6, 2025 | marketbeat.comBoothbay Fund Management LLC Takes Position in Inhibrx, Inc. (NASDAQ:INBX)May 4, 2025 | marketbeat.comInhibrx Biosciences reshuffles leadership, appoints new CSO and PresidentApril 3, 2025 | investing.comInhibrx announces leadership changes as co-founder departsApril 2, 2025 | thepharmaletter.comInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and PresidentApril 1, 2025 | prnewswire.comInhibrx Biosciences Full Year 2024 Earnings: Beats ExpectationsMarch 19, 2025 | finance.yahoo.comInhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 18, 2025 | finanznachrichten.deInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 17, 2025 | prnewswire.comWhen the Price of (INBX) Talks, People ListenFebruary 12, 2025 | news.stocktradersdaily.comWhy Inhibrx Biosciences, Inc.’s (INBX) Stock Is Up 10.07%January 31, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADVM, DMAC, ELDN, and INBX Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$2.51 +0.08 (+3.29%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$2.52 +0.02 (+0.60%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.DiaMedica Therapeutics NASDAQ:DMAC$4.12 -0.05 (-1.20%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$4.20 +0.09 (+2.06%) As of 06/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Eledon Pharmaceuticals NASDAQ:ELDN$3.17 +0.11 (+3.59%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$3.11 -0.06 (-1.92%) As of 06/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Inhibrx NASDAQ:INBX$13.53 +0.57 (+4.40%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$13.52 -0.01 (-0.07%) As of 06/3/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
